Optimal antiplatelet therapy after coronary stenting,a single-center randomized controlled pilot study
- VernacularTitle:冠状动脉支架术后优化抗血小板治疗的单中心随机对照预试验
- Author:
Yi LI
;
Yaling HAN
;
Shouli WANG
- Publication Type:Journal Article
- Keywords:
blood platelets,aspirin,clopidogrel,cilostazol;
angioplasty,transluminal,percutaneous coronary
- From:
Medical Journal of Chinese People's Liberation Army
2001;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility and efficacy of an optimized antiplatelet therapy according to laboratory test after coronary stenting.Methods Between June 2006 and February 2007,a total of 305 patients who underwent coronary stenting in General Hospital of Shenyang Command were enrolled.Patients were randomly assigned to receive optimized(optimal group,n=154)or standard antiplatelet therapy(standard group,n=151).Clopidogrel resistance(CR)was defined as a less than 10% reduction of platelet aggregation at 24h after clopidogrel treatment.The antiplatelet regimen for standard group was dual antiplatelet therapy with aspirin and clopidogrel.In optimal group,CR patients received cilostazol for 6 months in addition to dual anitplatelet therapy,whereas non-CR patients received standard dual antiplatelet therapy.The primary endpoint of present study was the composite analysis of death,myocardial infarction(MI)or stroke.Secondary endpoint was the composite analysis of death,MI,stroke,revascularization or peripheral artery occlusion.Results There were 41 and 33 CR patients in optimal and standard group,respectively.Cilostazol in addition to dual antiplatelet therapy decreased significantly the PAR of CR patients in optimal group(77.5%?12.1% vs 64.5%?12.1%,P
